KNSA Earnings Date: Feb 23, 2027 (Estimated) — Kiniksa Pharmaceuticals International, plc
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Updated
When is KNSA's next earnings date?
Kiniksa Pharmaceuticals International, plc (KNSA) is expected to report Q4 2026 earnings on Tuesday, February 23, 2027 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.31 on revenue of $276.4M.
How did KNSA do in its last earnings report?
In its most recent report on Oct 27, 2026 (Q3 2026), Kiniksa Pharmaceuticals International, plc posted EPS of $0.56 versus the $0.37 estimate, a beat of 50.9%. Revenue was $286.0M against a $260.7M estimate. The stock's 1-day post-earnings move was +22.2%.
How much does KNSA stock move after earnings?
KNSA beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 14.4% (up or down) in the day after earnings.
About Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
🤖 AI Earnings Analysis
Kiniksa’s ARCALYST momentum is strong: Q3 product revenue rose 58% to $286 million, beating estimates, and management raised 2026 revenue guidance to $1.045–$1.050 billion. EPS of $0.56 also topped consensus by $0.17.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-27 | Q3 2026 | 0.37 | 0.56 | +50.94% | $286.0M | ✅ Beat | +22.23% | — | — |
| 2026-07-28 | Q2 2026 | 0.30 | 0.30 | +0.00% | $243.6M | ➖ Inline | +25.03% | +15.54% | +26.23% |
| 2026-04-28 | Q1 2026 | 0.16 | 0.27 | +68.75% | $214.3M | ✅ Beat | +23.48% | +32.13% | +18.87% |
| 2026-02-24 | Q4 2025 | 0.35 | 0.17 | -51.43% | $202.1M | ❌ Miss | -8.21% | -2.93% | -5.17% |
| 2025-10-28 | Q3 2025 | 0.35 | 0.23 | -34.29% | $180.9M | ❌ Miss | -2.88% | -7.71% | +5.20% |
| 2025-07-29 | Q2 2025 | 0.21 | 0.23 | +9.52% | $156.8M | ✅ Beat | +12.32% | +21.86% | +24.15% |
| 2025-04-29 | Q1 2025 | 0.28 | 0.11 | -60.71% | $137.8M | ❌ Miss | +20.54% | +29.39% | +26.97% |
| 2025-02-25 | Q4 2024 | 0.13 | -0.12 | -192.31% | $122.5M | ❌ Miss | +0.46% | +9.32% | +18.14% |
Showing last 8 quarters.